PRDM2抗体;PRDM2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P11891(PRDM2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11891(PRDM2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The PRDM2 antibody is a crucial tool for studying the PR domain-containing protein 2 (PRDM2), also known as RIZ1 (Retinoblastoma-Interacting Zinc Finger Protein 1). PRDM2 belongs to the PR/SET domain protein family, which regulates gene expression through chromatin modification and transcriptional control. Structurally, it contains an N-terminal PR (PRDI-BF1-RIZ1 homologous) domain with histone methyltransferase activity and C-terminal zinc finger motifs for DNA binding. Functionally, PRDM2 acts as a tumor suppressor by modulating pathways involved in cell cycle arrest, apoptosis, and differentiation. Its loss or inactivation is linked to various cancers, including breast, liver, and colorectal carcinomas.

PRDM2 antibodies are widely used in research to detect and quantify PRDM2 expression in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate PRDM2’s role in epigenetic regulation, its interaction with retinoblastoma protein (pRb), and its involvement in cancer progression. Due to PRDM2’s alternative splicing into two isoforms (RIZ1 and RIZ2), antibody specificity is critical, requiring validation against knockout controls. Researchers also utilize PRDM2 antibodies to explore its methylation-dependent repression of oncogenes and potential therapeutic applications. Commercial PRDM2 antibodies are typically raised against epitopes within the PR domain or zinc finger regions, with monoclonal and polyclonal options available. Rigorous validation ensures reliability in both experimental and clinical research contexts.